(Nasdaq: CTOR) Climbs To A New 3+ Week High (Trends Above Key Technical Chart Levels)

Citius Oncology, Inc. (Nasdaq: CTOR) has a firm grip on my top watchlist spot this Monday.

*Sponsored (Nasdaq: CTOR) Climbs To A New 3+ Week High (Trends Above Key Technical Chart Levels) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* December 1st Greetings, Friend! Citius Oncology, Inc. (Nasdaq: CTOR) has a firm grip on my top watchlist spot this Monday. Here's why... CTOR reached a high of $1.61+ this morning. That's a level it hasn't hit in 3+ weeks. Additionally, CTOR is a low float profile with under 4Mn shares available. This means volatility potential could be significantly heighted daily. Plus, at the time of putting this update together, CTOR had moved above 4 key technical chart levels signaling a bullish trend may unfolding. Furthermore, a Maxim Group $6.00 analyst target hints there may be triple-digit potential upside in CTOR's future. As commercialization efforts keep ramping up (check the news below), strong buzz may envelop this under-the-radar Nasdaq Biopharma when an official announcement is made. Review my initial (Nasdaq: CTOR) report below and this about getting this one on your watchlist. ----- An emerging oncology company is nearing a pivotal transition in its story. Years of concentrated development and partnership-building have led to the brink of a crucial commercial debut that could significantly elevate its role in cancer treatment. The company is bringing forward a novel therapy designed to improve outcomes and fill important gaps in existing options, signaling a shift from purely clinical achievements to real-world commercial execution. The coming stage is expected to bring greater visibility, stronger operating traction, and real impact in a high-need therapeutic area. With a low float share structure that may amplify volatility, an analyst price target suggesting substantial upside potential, and a commercial launch slated for this quarter, this little-known Nasdaq profile currently sits at the top of my watchlist: Citius Oncology, Inc. (Nasdaq: CTOR) Citius Oncology, Inc. is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400Mn, is growing, and is underserved by existing therapies. (1) Company Overview - Citius Oncology, Inc. (Nasdaq: CTOR) Biopharmaceutical company focused on developing and commercializing innovative targeted  #1. Lead product, LYMPHIR, FDA approved August 2024 Orphan Indication: treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy 12-year BLA exclusivity First new systemic CTCL therapy since 2018  #2. Commercialization planned for Q4 2025 #3. Estimated $400Mn+ addressable U.S. market with growth opp's(1) #4. Publicly traded on NASDAQ since August 2024 (Ticker: CTOR) Citius Oncology, Inc. (Nasdaq: CTOR) Preps For Launch Of Lymphir In Q4 2025 Commercial launch readiness nearing completion through disciplined financial strategy What Exactly Is Cutaneous T-Cell Lymphoma (CTCL)? Considered to be incurable, CTCL is a Subgroup of Non-Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells Patients with persistent or recurrent CTCL require systemic therapy. 1. Dummer R, et al. Nat Rev Dis Primers. 2021;7(1):61. 2. Rangoonwala, HI and Cascella M. 2022, StatPearls Publishing: Treasure Island, FL. 3. Cleveland Clinic. Cutaneous T-Cell Lymphoma. 2023. Available from: https0://my.clevelandclinic.org/health/diseases/17940-cutaneous-t-cell-lymphoma 4. Hristov AC, et al. Am J Hematol. 2019;94(9):1027-1041 Convincing Clinical Findings  LYMPHIR addresses CTCL’s heavy Quality of Life burden 1. Objective Response is Complete Response and Partial Response according to the ISCL/EORTC Global Response Score. 2. In the Primary Efficacy Analysis set, 84.4% (54/64) of skin evaluable subjects had a decrease in skin tumor burden, with 48.4% subjects with ≥50% reduction in skin tumor burden. Complete clearing of skin disease (skin CR) was observed in 12.5% (8/64)subjects. 3. The duration of response (DOR) was at least 6 months for 52% of responders and at least 12 months for 20% of responders (25/69 patients). Potential For Expansion Beyond Cutaneous T-cell Lymphoma (CTCL) University of Pittsburgh: an investigator-initiated trial is underway to evaluate LYMPHIR for potential use as an immuno-oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) Encouraging preliminary results of interim analysis: 15 evaluable patients showed 27% ORR; 33% Clinical Benefit Rate; median Progression Free Survival of 57 weeks (for patients that achieved a clinical benefit) The data supports further evaluation of this combination across a broader range of solid tumor types. Phase 1 Preliminary study data (n=25) anticipated Q4 2025/Q1 2026. University of Minnesota: LYMPHIR in combination with CAR T therapies (NCT04855253) Phase 1 study to evaluate the potential benefit of LYMPHIR given prior to CAR T therapy in patients with high risk relapsed/refractory B-cell lymphomas. Preliminary study results anticipated Q1 2026. Logical label expansion potential in PTCL where there is a high unmet need and no curative therapies 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation. Find Sources And More Key Details Here: CTOR Presentation. ----- 5 Potential Catalysts Put (Nasdaq: CTOR) Atop Monday's Watchlist #1. Could A Low Float (Under 4Mn Shares) Create The Potential For A Volatile Environment? According to the Yahoo Finance website, CTOR has a very low float. In fact, the website reports this profile to have approximately 3.44Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could a commercial launch announcement towards the end of 2025 provide a breakout spark when paired with this volatility potential? #2. A Strong Analyst Target May Be Suggesting Serious Upside Potential. Over at the Maxim Group website, analyst Michael Okunewitch is providing CTOR with a $6 target. From Friday's closing valuation, that target suggests CTOR could have upside potential over 300%.  #3. Citius Oncology Strengthens LYMPHIR Launch Potential Through Innovative Verix AI Partnership. Citius Oncology, Inc. is advancing the U.S. commercial launch of LYMPHIR, its FDA-approved immunotherapy for relapsed or refractory Cutaneous T-cell Lymphoma, by integrating Verix’s AI-powered Tovana platform. This collaboration enhances data-driven sales and marketing strategies, enabling precise heal-thcare provider engagement and efficient resource allocation. With AI-guided targeting and real-time insights, the partnership positions Citius Oncology to achieve a focused, impactful launch and accelerate LYMPHIR’s adoption. The initiative demonstrates Citius Oncology’s commitment to innovation, operational excellence, and improved patient access while strengthening its growing oncology franchise. #4. Citius Oncology Strengthens LYMPHIR Access Through National McKesson Distribution Partnership. Citius Oncology, Inc. announced a U.S. distribution agreement with McKesson Corporation to support the commercial launch of LYMPHIR, an FDA-approved immunotherapy for relapsed or refractory Cutaneous T-cell Lymphoma. With McKesson now onboard, Citius Oncology has completed its top-tier distribution network, ensuring nationwide access through the three largest pharmaceutical distributors.  This milestone reinforces the company’s commitment to timely patient access and operational excellence. The partnership positions Citius Oncology for a strong fourth quarter 2025 launch, supported by robust infrastructure, permanent reimbursement coding, and comprehensive provider and patient outreach initiatives. #5. Citius Oncology Accelerates Towards LYMPHIR's Launch Through Exclusive EVERSANA Commercial Partnership. Citius Oncology, Inc. has entered an exclusive commercialization agreement with EVERSANA to support the U.S. launch of LYMPHIR, its FDA-approved therapy for relapsed or refractory Cutaneous T-cell Lymphoma. Under this partnership, EVERSANA will deliver integrated services including medical information, pharmacovigilance, and analytics, enhancing Citius Oncology’s operational readiness for a fourth-quarter 2025 debut. The collaboration expands on previous pre-commercial efforts, providing best-in-class infrastructure and oncology expertise. This milestone strengthens Citius Oncology’s market-launch capabilities, ensures efficient access for patients, and reinforces the company’s strategic focus on value creation and sustainable growth. ----- We're officially kicking-off coverage on Citius Oncology, Inc. (Nasdaq: CTOR). As soon as updates are available, I'll fire them out to you quickly. Talk soon.. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/30/2025 and ending on 12/01/2025 to publicly disseminate information about (CTOR:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CTOR:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ctor-icnzj/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice